Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
Panelists discuss the protocol for long-term monitoring of patients who receive chimeric antigen receptor (CAR) T-cell therapy, focusing on relapse prevention and overall health, as well as the impact of CAR T-cell therapy on long-term management of patients with standard-risk disease, including additional steps to monitor disease progression and ongoing support in the months and years following treatment.
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
What is the protocol for long-term monitoring of patients who receive chimeric antigen receptor (CAR) T-cell therapy in their treatment journey?
What specific factors do you focus on in terms of relapse prevention or overall health in these patients?
Dr Castaneda: Ask Jammie:
How does the use of CAR T-cell therapy affect your long-term management of patients with standard-risk disease? What additional steps do you take to monitor their disease progression?
Dr Castaneda: Ask Jammie:
How do you continue to support patients in the months and years following CAR T-cell therapy?
